We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
VistaGen Therapeutics Inc | NASDAQ:VTGN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.005 | -0.10% | 4.825 | 4.81 | 4.83 | 4.93 | 4.79 | 4.85 | 50,760 | 16:24:38 |
On November 6, 2017, VistaGen Therapeutics, Inc. (the "Company") announced that the European Patent Office (EPO) granted a European Patent for AV-101, the Company's oral CNS drug candidate in Phase 2 development for major depressive disorder (MDD). The patent relates to the treatment of depression, Parkinson's disease levodopa-induced dyskinesia (PD LID) and use of multiple dosage forms to treat these CNS disorders. The patent has been validated in Belgium, Denmark, France, Germany, Ireland, Italy, Portugal, Spain, Switzerland and the United Kingdom. It will be in effect until January 2034. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1, and is incorporated herein by reference.
See Exhibit List
VistaGen Therapeutics, Inc. |
By: | /s/ Shawn K. Singh |
|
|
Name: Shawn K. Singh | |
Title: Chief Executive Officer |
Exhibit No.
|
Description
|
|
EX-99.1
|
Press release issued by VistaGen Therapeutics Inc., dated November 6, 2017.
|
1 Year VistaGen Therapeutics Chart |
1 Month VistaGen Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions